Top Growth Stocks To Buy For 2019


The stock market mostly bounced higher on Wednesday following losses earlier in the week, with the Nasdaq Composite vaulting to new highs on strength in technology stocks. investors have gravitated toward the highest-growth areas of the market, leaving slower-growing value stocks behind in many cases. Good news from several individual companies also helped lift their share prices. Winnebago Industries (NYSE:WGO), Synaptics (NASDAQ:SYNA), and Tesaro (NASDAQ:TSRO) were among the best performers on the day. Here’s why they did so well.

Winnebago hits the gas

Shares of Winnebago Industries jumped 15% after the recreational vehicle specialist announced its fiscal third-quarter financial results. Winnebago said that sales climbed to record levels during the quarter, helping earnings jump by two-thirds from the year-ago period. As CEO Michael Happe noted, “New product performance, our evolving portfolio mix, and agility in managing cost pressures all contributed nicely to our third quarter results.” The only potential headwind down the road could come from inflationary pressure in obtaining the raw materials necessary to manufacture its RVs, but for the most part, Winnebago is confident that it can use cost-cutting measures elsewhere to insulate its bottom line from any potential negative impact.

Top Growth Stocks To Buy For 2019: iAnthus Capital Holdings, Inc. (ITHUF)


Advisors’ Opinion:

  • [By Spencer Israel]

    The charts below are courtesy of VantagePoint, a platform that uses Artificial Intelligence and machine learning to forecast future price movements 1-3 days in advance with up to 86 percent accuracy. The blue line represents a predictive moving average that shows what’s going to happen three days in advance, and the black line is a simple 10-day moving average. A crossover of the blue line over the black line indicates a bullish signal from the software, and vice versa for a bearish signal.


    iAthus Capital Holdings, Inc. (OTC: ITHUF)

    Up 94 percent YTD

  • [By Sean Williams]

    With this in mind, here are the pot stocks offering the highest revenue potential in fiscal 2019, listed in descending order:

    Aurora Cannabis (NYSE:ACB): $244.5 million The Green Organic Dutchman: $227.1 million Canopy Growth (NYSE:CGC): $190.4 million MedMen Enterprises: $188.9 million iAnthus Capital Holdings (NASDAQOTH:ITHUF): $181.4 million Village Farms International: $147.6 million GW Pharmaceuticals: $123 million KushCo Holdings (NASDAQOTH:KSHB): $117.9 million Aphria (NYSE:APHA): $107.4 million CannTrust Holdings: $105.5 million


    Image source: Getty Images.

  • [By Javier Hasse]

    Licensed cannabis production facilities owner and operator iAnthus Capital Holdings Inc (OTC: ITHUF) announced a $50 million investment from Gotham Green Partners. Management believes this is the largest investment to date by a single investor in a publicly traded U.S. cannabis operating company. iAnthus plans to allocate the proceeds of this financing to repay a $20 million one-year note and accrued interest to VCP Bridge LLC; continue to build out cultivation facilities and dispensaries in the New York and Florida markets; and, potentially, to expand activities. The remaining expenditures for completing iAnthus’ Massachusetts and Vermont operations will be funded with current cash on hand, management assured.

  • [By Javier Hasse]

    Here are some of the top marijuana stocks in U.S. exchanges and how the performed over the last five trading days (percentages reflect approximate equity moves as of the time of the writing of this article.

    22nd Century Group Inc (NYSE: XXII): up 4.5 percent
    Aphria Inc (OTC: APHQF): down 1.4 percent
    Aurora Cannabis Inc (OTC: ACBFF): up 0.6 percent
    Cannabis Sativa Inc (OTC: CBDS): down 6.3 percent
    CannTrust Holdings Inc (OTC: CNTTF): down 3.3 percent
    Canopy Growth Corp (NYSE: CGC): up 1.8 percent
    Cronos Group Inc. (NASDAQ: CRON): up 9.3 percent
    GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH): up 2.2 percent
    Hiku Brands Company Ltd(OTC: DJACF): down 15.5 percent
    India Globalization Capital, Inc. (NYSE: IGC): down 1.9 percent
    iAnthus Capital Holdings Inc (OTC: ITHUF): up 4.6 percent
    MassRoots Inc (OTC: MSRT): down 0.2 percent
    MedReleaf Corp(OTC: MEDFF): up 1.1 percent
    Scotts Miracle-Gro Co (NYSE: SMG): down 3.6 percent
    THC Biomed Intl Ltd (OTC: THCBF): down 5.5 percent
    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE): up 7.3 percent
    In Other News


    A consortium of cannabis-related media professionals are conducting a Cannabis Media Survey. You can answer following this link.

  • [By Sean Williams]

    For instance, iAnthus Capital Holding (NASDAQOTH:ITHUF) recently completed the largest U.S. deal to date by purchasing MPX Bioceutical for around $600 million. (This deal will be eclipsed by MedMen’s purchase of PharmaCann, once that deal closes.) Though it’s unclear what sort of premium iAnthus paid for MPX Bioceutical as of yet, a quick glance at iAnthus Capital’s balance sheet shows that 55% of its total assets are currently tied up in goodwill. Since the dispensary space will presumably have plenty of competition, it’s unclear if iAnthus (or other acquisition-hungry dispensaries) will be able to recoup the premium it’s paid to buy other businesses. This leaves the door open for hefty future writedowns.

Top Growth Stocks To Buy For 2019: Clearside BioMedical, Inc. (CLSD)


Advisors’ Opinion:

  • [By Brian Orelli]

    Shares of Clearside Biomedical (NASDAQ:CLSD) are down 26% at 12:47 p.m. EDT after the company announced what it called “positive topline results” from the phase 2 Tybee trial testing its steroid treatment, CLS-TA, in patients with an eye disease called diabetic macular edema.

  • [By Shane Hupp]

    MetLife Investment Advisors LLC purchased a new position in shares of Clearside Biomedical Inc (NASDAQ:CLSD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,859 shares of the company’s stock, valued at approximately $117,000.

  • [By Chris Lange]

    Clearside Biomedical Inc. (NASDAQ: CLSD) shares dropped early on Thursday after the company released data from its midstage clinical trial for diabetic macular edema (DME). Specifically, this data came from the Phase 2 clinical trial (TYBEE) evaluating suprachoroidal CLS-TA used with intravitreally administered Eylea (aflibercept).

  • [By Ethan Ryder]

    Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

    Get Catabasis Pharmaceuticals alerts:


    Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (NASDAQ: CLSD) and Bluebird Bio (NASDAQ … (analystratings.com) Catabasis launches public equity offering (seekingalpha.com) Friedreich Ataxia Market Pipeline Therapeutics 2018 Top Key Players, Drug Profile and Product Description (thecleantechnology.com) Cellectis SA Receives a Buy from Oppenheimer (analystratings.com) Global Type I Hyperlipoproteinemia Drug Market 2018- Catabasis Pharmaceuticals, Inc., uniQure NV , Isis … (afinancialanalysis.com)


    Shares of Catabasis Pharmaceuticals traded down $0.28, reaching $1.06, on Monday, Marketbeat reports. The company’s stock had a trading volume of 2,344,684 shares, compared to its average volume of 645,019. The firm has a market cap of $38.91 million, a price-to-earnings ratio of -0.84 and a beta of 0.74. Catabasis Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $3.78.

  • [By Ethan Ryder]

    Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have earned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.40.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Clearside Biomedical, Inc. (NASDAQ: CLSD) shares fell 17.8 percent to $11.95 in pre-market trading. Clearside Biomedical disclosed that its Phase 2 trial of CLS-TA met primary and secondary endpoints met in 6-month trial.
    CRISPR Therapeutics AG (NASDAQ: CRSP) fell 15.8 percent to $62.00 in pre-market trading after the company disclosed that the FDA has placed a clinical hold on IND for CTX001 sickle cell disease treatment.
    Sears Holdings Corporation (NASDAQ: SHLD) fell 10 percent to $2.89 in pre-market trading after the company posted a loss for the first quarter and announced plans to close 72 non-profitable stores.
    Urban One, Inc. (NASDAQ: UONE) fell 9 percent to $3.01 in pre-market trading after rising 78.38 percent on Wednesday.
    Dollar Tree, Inc. (NASDAQ: DLTR) shares fell 8.6 percent to $88.05 in pre-market trading after the company reported weaker-than-expected earnings for its first quarter and lowered its FY2018 earnings guidance.
    Ciena Corporation (NYSE: CIEN) fell 8.5 percent to $22.02 in the pre-market trading session after the company posted downbeat Q1 earnings and announced plans to buy Packet Design.
    Dollar General Corporation (NYSE: DG) shares fell 6.6 percent to $90.11 in pre-market trading after reporting weaker-than-expected results for its first quarter.
    Vericel Corp (NASDAQ: VCEL) shares fell 6.5 percent to $13.05 in pre-market trading following announcement of 3.75 million share common stock offering.
    Box, Inc. (NYSE: BOX) fell 5.7 percent to $26.19 in pre-market trading. Box reported upbeat results for its first quarter. The company forecast Q2 revenue of $146 million to $147 million.
    Co-Diagnostics, Inc. (NASDAQ: CODX) fell 5.7 percent to $3.15 in pre-market trading after declining 5.65 percent on Wednesday.
    Cherry Hill Mortgage Investment Corporation (NYSE: CHMI) shares fell 5.2 percent to $18.21 in pre-market trading after reporting a 2

Top Growth Stocks To Buy For 2019: E-House(China)


Advisors’ Opinion:

  • [By ]

    The world’s largest operating utility-scale solar projects are concentrated in China and India, according to IEEFA. Based on company and press reports, as well as its own estimates, those include:

    RankingProject NameSize MWCountryProponent 1Tengger Desert Solar Park1,547ChinaChina National Grid Zhongwei Power Supply Co2Kurnool Ultra Mega Solar Park1,000IndiaAndhra Pradesh Solar Power Corporation Pvt Ltd3Datong Solar Power Top Runner Base1,000ChinaMultiple4Yanchi Ningxia Solar Park1,000ChinaHuawei Technologies Co5Longyangxia Dam Solar Park850ChinaState Power Investment Corporation (China)6Adani Kamuthi Solar Plant648IndiaAdani Green7Solar Star579U.S.BHE Renewables8Topaz Solar Farm550U.S.First Solar9Desert Sunlight Solar Farm550U.S.NextEra Energy, GE Energy Financial & Sumitomo10Nova Olinda Solar Farm292BrazilEnel Green Power

    China added 53 gigawatts of the 98 gigawatts of new solar capacity built last year, a 31 percent increase from the total 2017, IEEFA said, citing Bloomberg New Energy Finance data. Meanwhile, the per unit cost of electricity over the life of a generating asset fell 15 percent year-on-year to $86 a megawatt hour.

Leave a Reply

Your email address will not be published.